1. A selective BCL-X
- Author
-
Sajid, Khan, Xuan, Zhang, Dongwen, Lv, Qi, Zhang, Yonghan, He, Peiyi, Zhang, Xingui, Liu, Dinesh, Thummuri, Yaxia, Yuan, Janet S, Wiegand, Jing, Pei, Weizhou, Zhang, Abhisheak, Sharma, Christopher R, McCurdy, Vinitha M, Kuruvilla, Natalia, Baran, Adolfo A, Ferrando, Yong-Mi, Kim, Anna, Rogojina, Peter J, Houghton, Guangcun, Huang, Robert, Hromas, Marina, Konopleva, Guangrong, Zheng, and Daohong, Zhou
- Subjects
Blood Platelets ,Sulfonamides ,Aniline Compounds ,bcl-X Protein ,Antineoplastic Agents ,Thrombocytopenia ,Article ,Gene Expression Regulation, Neoplastic ,Mice ,Von Hippel-Lindau Tumor Suppressor Protein ,Proteolysis ,Animals ,Heterografts ,Humans - Abstract
BCL-XL is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors such as ABT263 as safe and effective anticancer agents. To reduce the toxicity of ABT263, we converted it into DT2216, a BCL-XL proteolysis targeting chimera (PROTAC), that targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation. We found that DT2216 was more potent against various BCL-XL-dependent leukemia and cancer cells but significantly less toxic to platelets than ABT263 in vitro because VHL is poorly expressed in platelets. In vivo, DT2216 effectively inhibits the growth of several xenograft tumors as a single agent or in combination with other chemotherapeutic agents, without causing significant thrombocytopenia. These findings demonstrate the potential to use PROTAC technology to reduce on-target drug toxicities and rescue the therapeutic potential of previously undruggable targets. Furthermore, DT2216 may be developed as a safe first-in-class anticancer agent targeting BCL-XL.
- Published
- 2019